45.3% of the 12 mg administration group lost more than 30% of their weight, and 27.2% lost more than 35%
Acknowledgments We thank Steven Spitalnik for his thoughtful critiques and suggestions to improve our manuscript
los agonistas GLP-1 disponibles son inyectables u orales y se usan como terapia crnica mientras demuestren beneficio clnico y buena tolerabilidad
mRESVIA won approval based on the Phase III ConquerRSV trial, a global study of around 37,000 adults aged 60 or older in 22 countries, in which it displayed an efficacy rate of 83.7% against RSV lower respiratory tract disease
This may be due to the medication directly, or as a result of other side effects like vomiting, which can lead to dehydration
Medications that impact saliva flow or introduce acid to the oral cavity have long been known to increase dental risk